A Pilot Study of Cystic Volume Reduction by Foam Sclerotherapy in Autosomal Dominant Polycystic Kidney Disease
Tolvaptan is not able to address existing cyst burden in patients with autosomal dominant polycystic kidney disease (ADPKD).
Background
ADPKD is the most common inherited kidney disorder worldwide with a prevalence between 1:400 and 1:1000. Patients eventually develop kidney failure and require dialysis.
Tolvaptan is the only treatment approved in Canada. Tolvaptan reduces further growth of cysts but does not reduce the cyst burden. Foam sclerotherapy is a novel treatment able to permanently shrink the size of cysts with minimal reported side effects.
From 2014 to 2016, more than 60 patients underwent an experimental foam sclerotherapy procedure at Toronto General Hospital (TGH) with promising results!
Project team
- Dr. Ioan-Andrei Iliuta
TRP supervisors
Project advisory committee
- Dr. Anna Gagliardi, Senior Scientist, Toronto General Hospital Research Institute (TGHRI)
- Dr. Eran Shlomovitz, Assistant Professor, University of Toronto Department of Surgery
- Dr. York P-C Pei, Senior Scientist, Toronto General Hospital Research Institute (TGHRI)
See our community directory for more on committee members.